Discussion
The first participants have been enrolled in a global clinical trial that will test Priovant Therapeutics’ oral therapy candidate brepocitinib against a placebo in people with cutaneous sarcoidosis (CS) — a type of the autoimmune disease, with no approved treatments, in which clumps of immune cells form in…